These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38734990)

  • 1. Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification.
    Greenland NY; Cooperberg MR; Carroll PR; Cowan JE; Simko JP; Stohr BA; Chan E
    Prostate; 2024 Aug; 84(11):1076-1085. PubMed ID: 38734990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percentage Gleason pattern 4 and PI-RADS score predict upgrading in biopsy Grade Group 2 prostate cancer patients without cribriform pattern.
    van der Slot MA; Seyrek N; Kweldam CF; den Bakker MA; Busstra MB; Gan M; Klaver S; Rietbergen JBW; van Leenders GJLH
    World J Urol; 2022 Nov; 40(11):2723-2729. PubMed ID: 36190529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
    Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
    Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    van Leenders GJLH; Kweldam CF; Hollemans E; Kümmerlin IP; Nieboer D; Verhoef EI; Remmers S; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ
    Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic potential to regional lymph nodes with Gleason score ≤7, including tertiary pattern 5, at radical prostatectomy.
    Diolombi ML; Epstein JI
    BJU Int; 2017 Jun; 119(6):872-878. PubMed ID: 27496532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
    Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
    Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.
    Guo CC; Epstein JI
    Mod Pathol; 2006 Dec; 19(12):1528-35. PubMed ID: 16980940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.
    Shah RB; Nguyen JK; Przybycin CG; Reynolds JP; Cox R; Myles J; Klein E; McKenney JK
    Histopathology; 2019 Sep; 75(3):346-353. PubMed ID: 31012493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4.
    Greenland NY; Cowan JE; Zhang L; Carroll PR; Chan E; Stohr BA; Simko JP
    Prostate; 2020 May; 80(8):653-659. PubMed ID: 32220141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gleason score 5 + 3 = 8 (grade group 4) prostate cancer-a rare occurrence with contemporary grading.
    Kryvenko ON; Williamson SR; Schwartz LE; Epstein JI
    Hum Pathol; 2020 Mar; 97():40-51. PubMed ID: 31923450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
    Taylor AS; Morgan TM; Wallington DG; Chinnaiyan AM; Spratt DE; Mehra R
    Prostate; 2020 Feb; 80(2):146-152. PubMed ID: 31737920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIN-like (Ductal) Adenocarcinoma of the Prostate.
    Paulk A; Giannico G; Epstein JI
    Am J Surg Pathol; 2018 Dec; 42(12):1693-1700. PubMed ID: 30138215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
    Seyrek N; Hollemans E; Andrinopoulou ER; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Remmers S; Schoots IG; van Leenders GJLH
    Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.
    Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Roobol MJ; Helleman J; van Leenders GJLH
    Histopathology; 2020 Apr; 76(5):755-762. PubMed ID: 31944367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
    Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer.
    Czaja RC; Tarima S; Wu R; Palagnmonthip W; Iczkowski KA
    Ann Diagn Pathol; 2021 Jun; 52():151725. PubMed ID: 33610958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.
    Shah RB; Magi-Galluzzi C; Han B; Zhou M
    Am J Surg Pathol; 2010 Apr; 34(4):470-7. PubMed ID: 20182345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
    Epstein JI; Amin MB; Fine SW; Algaba F; Aron M; Baydar DE; Beltran AL; Brimo F; Cheville JC; Colecchia M; Comperat E; da Cunha IW; Delprado W; DeMarzo AM; Giannico GA; Gordetsky JB; Guo CC; Hansel DE; Hirsch MS; Huang J; Humphrey PA; Jimenez RE; Khani F; Kong Q; Kryvenko ON; Kunju LP; Lal P; Latour M; Lotan T; Maclean F; Magi-Galluzzi C; Mehra R; Menon S; Miyamoto H; Montironi R; Netto GJ; Nguyen JK; Osunkoya AO; Parwani A; Robinson BD; Rubin MA; Shah RB; So JS; Takahashi H; Tavora F; Tretiakova MS; True L; Wobker SE; Yang XJ; Zhou M; Zynger DL; Trpkov K
    Arch Pathol Lab Med; 2021 Apr; 145(4):461-493. PubMed ID: 32589068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores.
    Okubo Y; Sato S; Hasegawa C; Koizumi M; Suzuki T; Yamamoto Y; Yoshioka E; Ono K; Washimi K; Yokose T; Kishida T; Miyagi Y
    Hum Pathol; 2023 May; 135():99-107. PubMed ID: 36738975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.